By judgment of 23 January 2018, the Court of Justice of the EU addressed the competition law implications of off-label uses of medicines concerning the definition of the relevant market, ancillary restrictions to licensing agreements, and the dissemination of misleading information on risks under conditions of scientific uncertainty.
Competition law implications of off label uses of medicines: F. Hoffmann La Roche Ltd and others v Autorità Garante della Concorrenza e del Mercato (AGCM)
A. Parziale
2018-01-01
Abstract
By judgment of 23 January 2018, the Court of Justice of the EU addressed the competition law implications of off-label uses of medicines concerning the definition of the relevant market, ancillary restrictions to licensing agreements, and the dissemination of misleading information on risks under conditions of scientific uncertainty.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
ECLR_Parziale.pdf
solo utenti autorizzati
Tipologia:
PDF Editoriale
Licenza:
Copyright dell'editore
Dimensione
2.72 MB
Formato
Adobe PDF
|
2.72 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
